This research is Trending!
August 29, 2026New England Journal of Medicine
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
Key result
One-time CTX310 CRISPR editing safely sustains reductions in ANGPTL3 and atherogenic lipids at 1 year.
Why the study?
Does one-time CRISPR-Cas9 gene editing with CTX310 safely reduce ANGPTL3 and atherogenic lipids?
Comparison
One-time CRISPR-Cas9 gene editing with CTX310 targeting ANGPTL3
Design
Phase 1a trial
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“What is compelling about this update is that the reductions in ANGPTL3, triglycerides, and LDL from a single infusion have persisted out to one-year, suggesting a sustained biological effect.”
“Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive. It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients.”
“For the first time, we've shown that a single-course in vivo CRISPR treatment can safely and durably lower ANGPTL3, leading to clinically meaningful reductions in triglycerides and LDL. These data provide strong support for continued advancement of CTX310 and our broader cardiovascular gene-editing portfolio.”
Implication
Early-phase safety supports advancing to efficacy trials; leaves open cardiovascular outcome benefits.
Key Points
- To evaluate the safety, tolerability, and 1-year durability of one-time CRISPR-Cas9 gene editing targeting ANGPTL3 with CTX310.
- Conducted a phase 1a clinical trial administering a single dose of CTX310 CRISPR-Cas9 gene-editing therapy.
- Assessed safety, dose-limiting toxicities, and circulating levels of ANGPTL3 and atherogenic lipids through 1 year of follow-up.
- Treatment with CTX310 was well tolerated, with no reported treatment-related dose-limiting toxic effects.
- A single administration achieved sustained reductions in circulating ANGPTL3 and atherogenic lipids at 1 year.
Structured PICO
Does one-time CRISPR-Cas9 gene editing with CTX310 safely reduce ANGPTL3 and atherogenic lipids?
P
Population
Participants in a phase 1a trial
I
Intervention
One-time CRISPR-Cas9 gene editing with CTX310 targeting ANGPTL3
O
Outcome
Treatment-related dose-limiting toxic effects and reductions in ANGPTL3 and atherogenic lipids at 1 yearsafety
One-time CRISPR-Cas9 gene editing with CTX310 demonstrates early safety and sustained efficacy in reducing atherogenic lipids at 1 year.
Cite This Study
Laffin et al. (2026) studied this question. One-time CRISPR-Cas9 gene editing with CTX310 resulted in no treatment-related dose-limiting toxic effects and sustained reductions in ANGPTL3 and atherogenic lipids at 1 year.